KRas inhibitors (Nimbus Therapeutics)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameKRas inhibitors (Nimbus Therapeutics)
Drug Alias NameKRas inhibitors (Nimbus Discovery)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNimbus Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNimbus Therapeutics LLC
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A